The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy
Abstract
As hepatic stellate cells (HSCs) are essential for hepatic fibrogenesis, HSCs targeted nano-drug delivery system is a research hotspot in liver fibrosis therapy. However, the excessive deposition of fibrosis collagen (mainly collagen I) in the space of Disse associated with hepatic fibrogenesis would significantly hinder nano-formulation delivery to HSCs. Here, we have prepared a collagenase I and retinol co-decorated polymeric micelle that possess nanodrill-like and HSCs-target function based on poly-(lactic-co-glycolic)-b-poly (ethylene glycol)-maleimide (PLGA-PEG-Mal) (named CRM) for liver fibrosis therapy. Upon encountering collagen I barrier, CRM exerted a nanodrill-like function, efficiently degrading pericellular collagen I and showing greater uptake by human HSCs than other micelle formulations. Besides, CRM could realize excellent accumulation in the fibrotic liver and accurate targeting to activated HSCs in mouse hepatic fibrosis model. Moreover, CRM loaded with nilotinib (CRM/NIL), a second-generation tyrosine kinase inhibitor used in the treatment of liver fibrosis, showed optimal antifibrotic activity. This work suggests that CRM with dual function is an efficient carrier for liver fibrosis drug delivery and collagenase I decorating could be a new strategy for building more efficient HSCs targeted nano-drug delivery system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This may be associated with MFG‐E8 decreased the expression of the inflammatory cytokine via inhibited the p‐STAT3 pathway.[ 26 ]”
From An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis (2024) · cites this paper as [26]
Citations
Cites
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,388
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 911
Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 621
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10512 · Cited by 594
Self-citation
Cited by
Sorted by citations
Progress in Polymeric Micelles for Drug Delivery Applications
Kotta, S., Aldawsari, H. M., Badr-Eldin, S. M., Nair, A. B., & Kamal, Y. T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081636 · Cited by 241
Kumar, V., Xin, X., Ma, J., Tan, C., Osna, N. A., & Mahato, R. I. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113888 · Cited by 165
Shim, M. K., Yang, S., Sun, I., & Kim, K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114177 · Cited by 158
Rational design of polymeric micelles for targeted therapeutic delivery
Zheng, Y., Oz, Y., Gu, Y., Ahamad, N., Shariati, K., Chevalier, J. M., Kapur, D., & Annabi, N. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102147 · Cited by 119
Zhang, L.-F., Wang, X.-H., Zhang, C.-L., Lee, J., Duan, B.-W., Xing, L., Li, L., Oh, Y.-K., & Jiang, H.-L. (2022) · ACS Nano · doi:10.1021/acsnano.2c03858 · Cited by 92
Self-citation
Metadata
- Authors
- Fan, Q.-Q., Zhang, C.-L., Qiao, J.-B., Cui, P.-F., Xing, L., Oh, Y.-K., & Jiang, H.-L.
- Affiliations
- China Pharmaceutical University (CN)
- Seoul National University (KR)
- Corresponding author
- Oh, Yu-Kyoung
- Jiang, Hu-Lin
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 230
- Pages
- 119616
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2992864763
- Cited by
- 111
- References
- 38
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 26 · 2023: 22 · 2022: 17 · 2021: 10 · 2020: 10
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science and Technology Major Project (2017YFA0205400)
- National Natural Science Foundation of China (81773667, 81573369)
- International Cooperation and Exchanges (81811540416)
- First-class Project (CPU2018GY06)
- Ministry of Education of China
- State Administration of Foreign Experts Affairs of China (B16046)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- liver fibrosis, hepatic stellate cells, collagenase I, retinol, polymeric micelles, space of Disse, nilotinib, antifibrotic therapy
- MeSH terms
- Extracellular Matrix, Humans, Liver, Liver Cirrhosis, Micelles, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
